<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260623069931N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-08-11</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Virtual reality tourism for adult With Spinal Cord Injury</public_title>
      <acronym></acronym>
      <scientific_title>Effects of Adaptive Virtual Adventure Sport Tourism on Positive Affect and Well-Being in Adults With Spinal Cord Injury</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-08-16</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/92357</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Participants will be randomized individually in a 1:1 ratio to the adaptive VR intervention or active control group using computer-generated permuted blocks of four and six. Randomization will be stratified by neurological level (tetraplegia vs paraplegia) and baseline positive affect and well-being score (below vs at or above the sample median). An independent researcher not involved in recruitment, intervention delivery, or outcome assessment will generate the allocation sequence. Group assignments will be placed in sequentially numbered, opaque, sealed envelopes and opened by the intervention coordinator only after completion of baseline assessment, Blinding description: Participants and intervention personnel will not be blinded because of the visible differences between immersive VR and two-dimensional video viewing. Outcome assessments will be conducted by a research assistant who will not attend intervention sessions and will remain unaware of group allocation. Participants will be reminded not to disclose their assigned condition during assessments. For the primary analysis, groups will be coded as A and B, and the data analyst will remain blinded to group identity until the main analysis is completed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Spinal Cord Injury.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Participants will receive 12 supervised sessions of adaptive immersive virtual reality adventure sport tourism over 4 weeks, with 3 sessions per week. Using Meta Quest 3, participants will engage in virtual coastal kayaking, hand-cycling, wheelchair-accessible trail navigation, seated sailing, and destination exploration. Activities will be adapted to participants’ functional abilities and comfort. Intervention 2: Control group: Participants will receive 12 supervised sessions of non-immersive two-dimensional travel videos over 4 weeks, with 3 sessions per week. Videos will be viewed on a 24-inch monitor with session duration, setting, and facilitator contact matched to the intervention group. The control condition will not include immersion, motion tracking, interactive tasks, performance feedback, adaptive challenge, or active navigation.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Individual participant data will not be publicly shared to protect participant privacy and confidentiality</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hossein Faridniya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>16 Azar Street, Enghelab Square, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1417466191</zip>
        <telephone>+98 936 387 5989</telephone>
        <email>hossein.faridniya@ut.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hossein Faridniya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>16 Azar Street, Enghelab Square, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1417466191</zip>
        <telephone>+98 936 387 5989</telephone>
        <email>hossein.faridniya@ut.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18–65 years
Spinal cord injury for at least 6 months
AIS grade A–D
Ability to perform light-to-moderate upper-limb activity while seated
Adequate vision and hearing to participate in the intervention
Successful completion of the VR familiarization session</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>History of seizure within the past year
Severe vestibular disorder or motion sickness
Acute or uncontrolled autonomic dysreflexia
Unstable cardiovascular or respiratory condition
Active pressure injury
Severe uncorrected visual impairment
Acute psychiatric crisis
Cognitive or communication impairment preventing participation
Concurrent participation in another VR-based intervention
Planned change in mood-related medication during the study period</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G82</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Paraplegia (paraparesis) and quadriplegia (quadriparesis)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Participants will receive 12 supervised sessions of adaptive immersive virtual reality adventure sport tourism over 4 weeks, with 3 sessions per week. Using Meta Quest 3, participants will engage in virtual coastal kayaking, hand-cycling, wheelchair-accessible trail navigation, seated sailing, and destination exploration. Activities will be adapted to participants’ functional abilities and comfort</i_keyword>
      <i_keyword>Control group: Participants will receive 12 supervised sessions of non-immersive two-dimensional travel videos over 4 weeks, with 3 sessions per week. Videos will be viewed on a 24-inch monitor with session duration, setting, and facilitator contact matched to the intervention group. The control condition will not include immersion, motion tracking, interactive tasks, performance feedback, adaptive challenge, or active navigation</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>SCI-specific positive affect and well-being T-score. Timepoint: Baseline, 24–72 hours post-intervention, and 30-day follow-up. Method of measurement: SCI-QOL Positive Affect and Well-Being Short Form 10a (SCI-QOL PAWB SF10a).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-04-20</approval_date>
        <contact_name>Sport Sciences Research Institute Ethics Committee</contact_name>
        <contact_address>No. 3, 5th Alley, Mir Emad St., Ostad Motahari St., Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
